If I recall correctly I believe a couple of follow-ons for the CD-20 MAB are in the works. I vaguely recall Inex (small canadian company) working on one before their RNA split (don't know where it stands now) I recall seeing at least one other company working on one but that eludes me. I don't think BIIB will let their Rituxan franchise slip anytime soon.
I am relatively new to GTC after seeing many of the posters are the same as on Biotech Values. I had thought GTC's Transgenic business was more a play on generic biologicals but after seeing this: "...and to have relatively higher antibody dependent cell-mediated cytotoxicity, or ADCC" I was wondering if GTC's follow-ons may provide some sort of benefit in efficacy/dosing/toxicity/etc.? Sorry if this has been addressed here before.
Market Data 
Markets 
AI
